Crystalline forms of macrocyclic peptide antibiotics
The toxicity, solubility and purification problems are solved through the novel forms of monohydrochloride (HCl salt) and free base of macrocyclic peptide antibiotics, and efficient drug manufacturing and simplified industrial-scale production are achieved.
Patent Information
- Application Number
- CN202380032881.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-07
- Filing Date
- 2023-04-05
- Publication Date
- 2024-11-15
AI Technical Summary
The tetra-tetrafluoroacetate form of existing macrocyclic peptide antibiotics has toxicity problems, free base is difficult to dissolve in water, and contains high levels of palladium and sodium chloride impurities, resulting in cumbersome purification steps and difficult to use in drug manufacturing.
Provides novel forms of monohydrochloride (HCl salt) and free bases of macrocyclic peptide antibiotics, especially their significantly improved water solubility and certain crystalline forms, which promote the purification of raw materials and allow industrial-scale manufacturing under GMP conditions. .
HCl salt significantly improves water solubility, simplifies the conditions for intravenous administration, and certain crystalline forms of free bases greatly reduce palladium and sodium chloride contamination, simplifies the purification process, and achieves industrial-scale drug manufacturing.
Smart Images

Figure BDA0005073167110000011 
Figure BDA0005073167110000021 
Figure BDA0005073167110000031
Abstract
Description
Technical Field
[0001] The present invention relates to novel monohydrochloride salts (hereinafter referred to as "HCl salts") and novel free zwitterions (hereinafter referred to as "free bases") of the macrocyclic peptide antibiotic 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid. The present invention also relates to amorphous forms and certain crystalline forms of the HCl salts and free bases. Finally, the present invention relates to pharmaceutical compositions comprising the novel forms, methods for their manufacture and their use in medical therapy. Background Art
[0002] WO2019206853, the entire contents of which are incorporated herein by reference, discloses a peptide macrocyclic 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (Formula Ia) having potent antibacterial properties.
[0003]
[0004] More specifically, WO2019206853 discloses a tetrafluoroacetic acid (TFA) salt of a compound of formula (Ia). However, due to the toxicity of the TFA salt, the TFA salt cannot be directly used as an active pharmaceutical ingredient for treating bacterial infections.
[0005] On the other hand, the "free base" (ie, free zwitterion) of the compound of formula (Ia) was found to be poorly soluble in water, which is unacceptable for a pharmaceutical compound intended for intravenous administration.
[0006] Furthermore, the API was found to contain high levels of palladium and sodium chloride impurities from the manufacturing process, which necessitated tedious purification steps (e.g., nanofiltration to remove sodium chloride). However, repeated purification is highly undesirable in large-scale manufacturing of pharmaceuticals.
[0007] In view of the above, there exists an unmet need for new forms of the compounds of formula (Ia) which ultimately enable the compounds to be used as pharmaceuticals for the treatment of bacterial infections. Summary of the invention
[0008] It has now been surprisingly found that the HCl salts described herein exhibit significantly increased solubility compared to the free base, especially in aqueous media, which is critical for intravenous administration.
[0009] Furthermore, it was surprisingly found that a certain crystalline form of the free base greatly facilitates the purification of the drug substance, allowing its manufacture on an industrial scale under GMP conditions.
[0010] Therefore, in a first aspect, the present invention provides the monohydrochloride salt of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (Formula I).
[0011]
[0012] In another aspect, the present invention provides certain crystalline forms and amorphous forms of the monohydrochloride salt of Formula (I) as described herein, as well as methods of making, methods of using, and pharmaceutical compositions comprising the same.
[0013] In another aspect, the present invention provides the free base of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid, i.e., the free zwitter ion (Formula Ia).
[0014]
[0015] In another aspect, the present invention provides certain crystalline forms and amorphous forms of the free base of Formula (Ia) as described herein, as well as methods of making, methods of using, and pharmaceutical compositions comprising the same. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The characteristic XRPD diffraction pattern of the crystalline polymorph Form A1 of the monohydrochloride salt of Formula (I) described in Example 3 is shown.
[0017] Figure 2 The characteristic FT Raman spectrum of the crystalline polymorph Form A1 of the monohydrochloride salt of formula (I) described in Example 3 is shown.
[0018] Figure 3 Shown is a characteristic ATR-FTIR spectrum of the crystalline polymorph Form A1 of the monohydrochloride salt of formula (I) described in Example 3.
[0019] Figure 4 The characteristic XRPD diffraction pattern of the crystalline polymorph Form A2 of the monohydrochloride salt of Formula (I) described in Example 4 is shown.
[0020] Figure 5 The characteristic FT Raman spectrum of the crystalline polymorph Form A2 of the monohydrochloride salt of formula (I) described in Example 4 is shown.
[0021] Figure 6 Shown is a characteristic ATR-FTIR spectrum of the crystalline polymorph Form A2 of the monohydrochloride salt of Formula (I) described in Example 4.
[0022] Figure 7 The characteristic XRPD diffraction pattern of the crystalline polymorph Form "Pattern 4" of the monohydrochloride salt of Formula (I) described in Example 5 is shown.
[0023] Figure 8 The characteristic XRPD diffraction pattern of the crystalline polymorph Form "Pattern 5" of the monohydrochloride salt of Formula (I) described in Example 6 is shown.
[0024] Fig. 9 Characteristic FT Raman spectra of the amorphous form of the monohydrochloride salt of formula (I) described in Example 2 and the amorphous form of the free base of formula (Ia) described in Example 7 are shown.
[0025] Fig.10 The characteristic ATR-FTIR spectrum of the amorphous form of the monohydrochloride salt of formula (I) described in Example 2 is shown.
[0026] Fig.11 The characteristic XRPD diffraction pattern of the crystalline polymorph Form A1 of the free base of Formula (Ia) described in Example 8 is shown.
[0027] Fig.12 Shown is the characteristic FT Raman spectrum of the crystalline polymorph Form A1 of the free base of formula (Ia) described in Example 8.
[0028] Fig.13 Shown is a characteristic ATR-FTIR spectrum of the crystalline polymorph Form A1 of the free base of formula (Ia) described in Example 8.
[0029] Fig.14 The characteristic XRPD diffraction pattern of the crystalline polymorph Form B of the free base of Formula (Ia) described in Examples 9 and 10 is shown.
[0030] Fig.15 The characteristic FT Raman spectrum of the crystalline polymorph Form B of the free base of formula (Ia) described in Examples 9 and 10 is shown.
[0031] Fig.16 Shown is a characteristic ATR-FTIR spectrum of the crystalline polymorph Form B of the free base of Formula (Ia) described in Examples 9 and 10.
[0032] Fig.17 The characteristic ATR-FTIR spectrum of the amorphous form of the free base of formula (Ia) described in Example 7 is shown.
[0033] Fig.18 The characteristic XRPD diffraction pattern of the crystalline polymorph Form "Pattern 10.1" of the free base of Formula (Ia) described in Example 11 is shown. DETAILED DESCRIPTION
[0034] definition
[0035] The terms "zwitterionic state", "free zwitterion" and "free base" are used interchangeably herein and refer to compounds of formula (Ia) in which the acidic carboxylic acid functional group is deprotonated (negatively charged) while one of the basic amino functional groups is protonated (positively charged).
[0036] The term "pharmaceutical composition" refers to a mixture of the crystalline and / or amorphous forms described herein with other chemical components such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, excipients, etc. The pharmaceutical composition facilitates administration of the compound to a mammal.
[0037] A "detectable amount" is a quantity that can be detected using standard analytical methods (e.g., ion chromatography, mass spectrometry, NMR, HPLC, gas chromatography, elemental analysis, IR spectroscopy, inductively coupled plasma atomic emission spectroscopy, USP <231> Method II, etc.) (ICH Guidelines, Q2A Text on Validation of Analytical Procedures (March 1995) and Q2B Validation of Analytical Procedures: Methodology (November 1996) for measurable quantities.
[0038] The term "acceptable" with respect to a formulation, composition or ingredient as used herein means having no persistent detrimental effect on the general health of the subject being treated.
[0039] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of the administered agent that will alleviate one or more symptoms of the disease or condition being treated to some extent. The result may be a reduction and / or alleviation of the signs, symptoms or causes of the disease or any other desired change in the biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein that is required to provide a clinically significant reduction in disease symptoms. The term "therapeutically effective amount" includes, for example, a preventive effective amount. The effective amount will be selected according to the specific patient and the level of disease. It should be understood that the "effective amount" or "therapeutically effective amount" varies between subjects due to changes in drug metabolism, age, weight, the general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician. In some embodiments, the appropriate "effective" amount in any individual case is determined using techniques such as dose escalation studies. In some embodiments, the term "effective amount" or "therapeutically effective amount" is used with reference to the crystalline or amorphous form described herein administered, which will alleviate one or more symptoms of the disease or condition being treated to some extent.
[0040] The terms "kit" and "article of manufacture" are used synonymously.
[0041] Crystalline and amorphous forms
[0042] In a first aspect, the present invention provides the monohydrochloride salt of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (Formula I, "HCl salt").
[0043]
[0044] Compared to the free base, the HCl salt of the present invention exhibits significantly increased solubility, especially in aqueous media, which is critical for intravenous administration (Example 14).
[0045] In one embodiment, the HCl salt of the present invention is crystalline and has a relative humidity of 5.16, 7.94, 9.98, 10.46, 10.78, 11.66, 17.28 and 18.90 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
[0046] In one embodiment, the HCl salt of the present invention is crystalline and:
[0047] (a) has an X-ray powder diffraction (XRPD) pattern with chromatic aberrations at 5.16, 7.94, 9.98, 10.46, 10.78, 11.66, 15.52, 15.70, 17.28 and 18.90 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes a peak; and / or
[0048] (b) has an FT Raman spectrum with a peak at about 103 cm -1 、1390cm -1 、2246cm -1 and 2930cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0049] (c) has an ATR-FTIR spectrum with a peak at about 752 cm -1 、1386cm -1 、1534cm -1 and 1602cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0050] In preferred embodiments, the HCl salts of the present invention are crystalline and:
[0051] (a) has an X-ray powder diffraction (XRPD) pattern with peaks at 5.16, 6.54, 7.94, 9.98, 10.46, 10.78, 11.54, 11.66, 11.98, 12.10, 13.02, 13.16, 14.38, 14.82, 15.04, 15.52, 15.70, 15.94, 16.74, 17.28, 17.74, 18.10, 18.32, 18.78, 18.90, 19.72, 20. 02, 20.28, 20.80, 20.96, 21.16, 21.56, 21.62, 22.38, 22.66, 23.28, 23.50, 23.98, 24.72, 24.92, 25.20, 25.60, 25.98, 26.22, 26.98, 27.20, 27.42, 27.88, 28.10, 28.48, 28.66, 29.00, 29.70, and 30.00 [°2θ ± 0.2°2θ, Cu Kα radiation ] includes a peak; and / or
[0052] (b) has an FT Raman spectrum with a peak at about 103 cm -1 、137cm -1、225cm -1 、279cm -1 、330cm -1 、382cm -1 、416cm -1 、449cm -1 、479cm -1 、517cm -1 、547cm -1 、563cm -1 、596cm -1 、624cm -1 、639cm -1 、685cm -1 、758cm -1 、790cm -1 、807cm -1 、848cm -1 、878cm -1 、898cm -1 、955cm -1 、1011cm -1 、1059cm -1 、1074cm -1 、1140cm -1 、1183cm -1 、1203cm -1 、1247cm -1 、1288cm -1 、1316cm -1 、1334cm -1 、1358cm -1 、1391cm -1 、1425cm -1 、1435cm -1 、1451cm -1 、1489cm -1 、1557cm -1 、1580cm -1 、1605cm -1 、1666cm -1 、2246cm -1 、2859cm -1 、2930cm -1 、2985cm -1 、3063cm -1 and 3116cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0053] (c) has an ATR-FTIR spectrum with a peak at about 659 cm-1 、717cm -1 、731cm -1 、752cm -1 、778cm -1 、786cm -1 、803cm -1 、847cm -1 、874cm -1 、887cm -1 、906cm -1 、931cm -1 、950cm -1 、971cm -1 、1010cm -1 、1017cm -1 、1080cm -1 、1098cm -1 、1134cm -1 、1148cm -1 、1180cm -1 、1215cm -1 、1248cm -1 、1282cm -1 、1334cm -1 、1385cm -1 、1439cm -1 、1459cm -1 、1534cm -1 、1602cm -1 、1659cm -1 、1682cm -1 、2936cm -1 、3054cm -1 、3239cm -1 and 3434cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0054] In particularly preferred embodiments, the HCl salts of the present invention are crystalline and:
[0055] (a) Having Figure 1 substantially the same X-ray powder diffraction (XRPD) pattern as shown; and / or
[0056] (b) Having Figure 2 substantially the same FT Raman spectrum as shown; and / or
[0057] (c) Having Figure 3 Essentially the same ATR-FTIR spectra are shown.
[0058] In one embodiment, the HCl salt of the present invention is crystalline and:
[0059] (a) has an X-ray powder diffraction (XRPD) pattern with chromatic aberrations at 5.20, 7.94, 9.92, 10.36, 10.68, 11.60, 15.58, 17.16 and 18.78 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes a peak; and / or
[0060] (b) has an FT Raman spectrum with a peak at about 163 cm -1 、1391cm -1 、2920cm -1 and 2948cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0061] (c) has an ATR-FTIR spectrum with a peak at about 753 cm -1 、1387cm -1 、1541cm -1 、1604cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0062] In preferred embodiments, the HCl salts of the present invention are crystalline and:
[0063] (a) has an X-ray powder diffraction (XRPD) pattern with peaks at 5.20, 6.52, 7.94, 9.92, 10.36, 10.68, 11.60, 12.04, 13.02, 13.10, 14.34, 14.70, 14.92, 15.58, 15.94, 16.68, 17.16, 17.52, 17.82, 18.06, 18.22, 18.78, 19.70, 19.80, 19.96, 20.64, 20. 88, 21.10, 21.50, 22.30, 22.58, 23.18, 23.44, 23.58, 23.94, 24.22, 24.70, 25.02, 25.42, 25.74, 26.18, 26.82, 27.04, 27.24, 27.72, 27.90, 28.34, 28.86, 29.10, 29.52, 29.74, 30.14, 31.08, and 31.52 [°2θ ± 0.2°2θ, Cu Kα radiation ] includes a peak; and / or
[0064] (b) has an FT Raman spectrum with a peak at about 107 cm-1 、135cm -1 、163cm -1 、225cm -1 、336cm -1 、417cm -1 、450cm -1 、480cm -1 、518cm -1 、546cm -1 、562cm -1 、596cm -1 、621cm -1 、639cm -1 、686cm -1 、758cm -1 、774cm -1 、790cm -1 、813cm -1 、848cm -1 、877cm -1 、899cm -1 、955cm -1 、1011cm -1 、1046cm -1 、1059cm -1 、1075cm -1 、1140cm -1 、1188cm -1 、1200cm -1 、1234cm -1 、1249cm -1 、1289cm -1 、1317cm -1 、1335cm -1 、1358cm -1 、1391cm -1 、1426cm -1 、1435cm -1 、1452cm -1 、1489cm -1 、1558cm -1 、1578cm -1 、1606cm -1 、1660cm -1 、2920cm -1 、2948cm -1 、2986cm -1 and 3059cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0065] (c) has an ATR-FTIR spectrum with a peak at about 673 cm -1 、718cm -1 、739cm -1 、753cm -1 、773cm -1 、779cm -1 、803cm -1 、848cm -1 、875cm -1 、888cm -1 、898cm -1 、906cm -1 、932cm -1 、946cm -1 、971cm -1 、1010cm -1 、1017cm -1 、1037cm -1 、1067cm -1 、1082cm -1 、1095cm -1 、1134cm -1 、1149cm -1 、1169cm -1 、1181cm -1 、1223cm -1 、1248cm -1 、1286cm -1 、1333cm -1 、1387cm -1 、1406cm -1 、1424cm -1 、1440cm -1 、1459cm -1 、1467cm -1 、1541cm -1 、1585cm -1 、1604cm -1 、1658cm -1 、2937cm -1 、3054cm -1 、3230cm -1 、3349cm -1 and 3429cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0066] In particularly preferred embodiments, the HCl salts of the present invention are crystalline and:
[0067] (a) Having Figure 4 substantially the same X-ray powder diffraction (XRPD) pattern as shown; and / or
[0068] (b) Having Figure 5 substantially the same FT Raman spectrum as shown; and / or
[0069] (c) Having Figure 6 Essentially the same ATR-FTIR spectra are shown.
[0070] In one embodiment, the HCl salt of the present invention is crystalline and has a relative humidity of 5.6, 7.14, 8.66, 9.92, 10.52, 10.88, 11.92, 15.6, 16.64, 17.7, and 20.94 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
[0071] In a preferred embodiment, the HCl salt of the present invention is crystalline and has Figure 7 Substantially the same X-ray powder diffraction (XRPD) pattern is shown.
[0072] In one embodiment, the HCl salt of the present invention is crystalline and has a relative humidity of 5.22, 8.16, 9.88, 10.04, 10.48, 10.8, 11.48, 11.72, 12.2, 12.58, 13.1, 13.62, 14.5, 14.82, 15.12, 15.7, 16.02, 17.02, 17.82, 18.16, 18.42, 18.58, 18.72, 18.9, 19.4, 19.62, and 19.84 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
[0073] In a preferred embodiment, the HCl salt of the present invention is crystalline and has Figure 8 Substantially the same X-ray powder diffraction (XRPD) pattern is shown.
[0074] In one embodiment, the HCl salt of the present invention is amorphous and:
[0075] (a) has an FT Raman spectrum with a peak at about 1296 cm -1 、1608cm -1 、2928cm -1 and 3060cm -1 ±2cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0076] (b) has an ATR-FTIR spectrum with a peak at about 742 cm -1 、778cm -1 、1377cm -1 and 1531cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0077] In preferred embodiments, the HCl salts of the present invention are amorphous and:
[0078] (a) has an FT Raman spectrum with a peak at about 334 cm -1 、415cm -1 、543cm -1 、641cm -1 、683cm -1 、759cm -1 、803cm -1 、842cm -1 、879cm -1 、912cm -1 、1011cm -1 、1061cm -1 、1077cm -1 、1137cm -1 、1203cm -1 、1296cm -1 、1359cm -1 、1381cm -1 、1437cm -1 、1453cm -1 、1557cm -1 、1579cm -1 、1609cm -1 、2928cm -1 and 3059cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0079] (b) has an ATR-FTIR spectrum with a peak at about 680 cm -1 、716cm -1 、742cm -1 、778cm -1 、841cm -1 、868cm -1 、1010cm -1 、1043cm -1 、1078cm -1 、1129cm -1 、1177cm-1 、1224cm -1 、1285cm -1 、1376cm -1 、1403cm -1 、1456cm -1 、1531cm -1 、1582cm -1 、1627cm -1 、2924cm -1 and 3243cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0080] In particularly preferred embodiments, the HCl salts of the present invention are amorphous and:
[0081] (a) Having Fig. 9 substantially the same FT Raman spectrum as shown; and / or
[0082] (b) Having Fig.10 Essentially the same ATR-FTIR spectra are shown.
[0083] In another aspect, the present invention provides the free base of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid, i.e., the free zwitter ion (Formula Ia).
[0084]
[0085] In one embodiment, the free base of the invention is crystalline.
[0086] In one embodiment, the free base of the invention is amorphous.
[0087] In one embodiment, the free base of the invention is crystalline and:
[0088] (a) has an X-ray powder diffraction (XRPD) pattern with chromatic aberrations at 5.46, 8.08, 10.36, 11.56, 11.86, 16.56 and 17.44 [°2θ±0.2°2θ, Cu Kα radiation ] includes a peak; and / or
[0089] (b) has an FT Raman spectrum with a peak at about 838 cm -1 、1079cm-1 、1373cm -1 and 1608cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0090] (c) has an ATR-FTIR spectrum with a peak at about 746 cm -1 、784cm -1 、1371cm -1 and 3437cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0091] In preferred embodiments, the free base of the invention is crystalline and:
[0092] (a) has an X-ray powder diffraction (XRPD) pattern with peaks at 5.46, 8.08, 9.90, 10.36, 11.56, 11.86, 12.46, 12.84, 13.36, 13.70, 13.86, 14.82, 14.98, 15.28, 16.56, 17.00, 17.44, 17.72, 18.18, 18.42, 18.64, 18.94, 19.26, 19.80, 20.12, 20. 52, 20.78, 21.02, 21.14, 21.34, 21.48, 21.66, 21.80, 22.74, 22.84, 23.22, 23.42, 23.72, 24.02, 24.42, 24.58, 25.10, 25.52, 25.92, 26.18, 26.96, 27.60, 27.82, 27.94, 28.64, 29.16, and 29.92 [°2θ ± 0.2°2θ, Cu Kα radiation ] includes a peak; and / or
[0093] (b) has an FT Raman spectrum with a peak at about 233 cm -1 、334cm -1 、415cm -1 、490cm -1 、540cm -1 、575cm -1 、596cm -1 、625cm -1 、642cm -1 、680cm -1 、699cm -1 、719cm -1 、757cm -1 、791cm -1 、810cm-1 、838cm -1 、879cm -1 、899cm -1 、1010cm -1 、1060cm -1 、1080cm -1 、1134cm -1 、1204cm -1 、1234cm -1 、1288cm -1 、1345cm -1 、1359cm -1 、1374cm -1 、1437cm -1 、1556cm -1 、1576cm -1 、1608cm -1 、2867cm -1 、2928cm -1 、3062cm -1 and 3114cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0094] (c) has an ATR-FTIR spectrum with a peak at about 676 cm -1 、716cm -1 、746cm -1 、774cm -1 、784cm -1 、838cm -1 、868cm -1 、904cm -1 、933cm -1 、1009cm -1 、1043cm -1 、1077cm -1 、1125cm -1 、1175cm -1 、1216cm -1 、1249cm -1 、1286cm -1 、1301cm -1 、1370cm -1 、1457cm -1 、1470cm -1 、1533cm -1 、1587cm -1 、1651cm -1 、2863cm -1、2927cm -1 、3041cm -1 、3223cm -1 and 3437cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0095] In particularly preferred embodiments, the free base of the invention is crystalline and:
[0096] (a) Having Fig.11 substantially the same X-ray powder diffraction (XRPD) pattern as shown; and / or
[0097] (b) Having Fig.12 substantially the same FT Raman spectrum as shown; and / or
[0098] (c) Having Fig.13 Essentially the same ATR-FTIR spectra are shown.
[0099] Surprisingly, it was found that the crystalline "Form B" of the free base greatly facilitates the purification of the API, allowing for industrial scale manufacture under GMP conditions. Thus, the crystalline "Form B" described in Example 10 shows significantly reduced levels of palladium and sodium chloride contamination compared to the amorphous form described in Example 7. Therefore, providing the API as a free base and crystallizing it as Form B is a useful strategy that avoids cumbersome nanofiltration to remove sodium chloride and further inefficient purification steps to reduce palladium contamination. Therefore, Form B of the free base is very useful in the manufacture of the API.
[0100] In one embodiment, the free base of the invention is crystalline and:
[0101] (a) has an X-ray powder diffraction (XRPD) pattern with chromatic aberrations at 6.6, 9.0, 9.9, 10.1, 11.8, 12.0, 14.5, 15.4 [°2θ±0.2°2θ, Cu Kα radiation ] includes a peak; and / or
[0102] (b) has an FT Raman spectrum with a peak at about 757 cm -1 、1290cm -1 、1433cm -1 and 1548cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0103] (c) has an ATR-FTIR spectrum with a peak at about 745 cm -1 、1367cm -1 、1533cm -1and 1638cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0104] In preferred embodiments, the free base of the invention is crystalline and:
[0105] (a) has an X-ray powder diffraction (XRPD) pattern, which
[0106] 6.6, 9.0, 9.9, 10.1, 11.8, 12.0, 14.5, 14.8, 15.4, 15.7, 16.0, 16.4, 16.7, 17.0, 17.8, 18.0, 18.4, 18.7, 19.1, 19.6, 20.0, 20.4, 20.7, 20.9, 21.2, 21.5, 22.1, 23.3, 23.8, 24.2, 24.6, 24.9, and 25.7 [°2θ ± 0.2°2θ, Cu Kα radiation ] includes a peak; and / or
[0107] (b) has an FT Raman spectrum with a peak at about 233 cm -1 、331cm -1 、352cm -1 、414cm -1 、462cm -1 、543cm -1 、574cm -1 、596cm -1 、614cm -1 、625cm -1 、641cm -1 、682cm -1 、696cm -1 、718cm -1 、757cm -1 、839cm -1 、878cm -1 、947cm -1 、1010cm -1 、1044cm -1 、1059cm -1 、1075cm -1 、1097cm -1 、1136cm -1 、1149cm -1 、1179cm -1 、1203cm -1 、1234cm -1 、1290cm -1 、1303cm-1 、1361cm -1 、1372cm -1 、1433cm -1 、1453cm -1 、1491cm -1 、1547cm -1 、1557cm -1 、1576cm -1 、1610cm -1 、1660cm -1 、2868cm -1 、2930cm -1 、3059cm -1 and 3113cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0108] (c) has an ATR-FTIR spectrum with a peak at about 677 cm -1 、716cm -1 、745cm -1 、771cm -1 、784cm -1 、801cm -1 、839cm -1 、868cm -1 、906cm -1 、927cm -1 、967cm -1 、1014cm -1 、1043cm -1 、1077cm -1 、1125cm -1 、1171cm -1 、1213cm -1 、1243cm -1 、1283cm -1 、1301cm -1 、1367cm -1 、1399cm -1 、1431cm -1 、1456cm -1 、1471cm -1 、1533cm -1 、1590cm -1 、1638cm -1 、1658cm -1 、1694cm -1 、2862cm -1 、2925cm -1、3029cm -1 and 3212cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0109] In particularly preferred embodiments, the free base of the invention is crystalline and:
[0110] (a) Having Fig.14 substantially the same X-ray powder diffraction (XRPD) pattern as shown; and / or
[0111] (b) Having Fig.15 substantially the same FT Raman spectrum as shown; and / or
[0112] (c) Having Fig.16 Essentially the same ATR-FTIR spectra are shown.
[0113] In one embodiment, the free base of the invention is amorphous and:
[0114] (a) has an FT Raman spectrum with a peak at about 1296 cm -1 、1608cm -1 、2928cm -1 and 3060cm -1 ±2cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0115] (b) has an ATR-FTIR spectrum with a peak at about 742 cm -1 、778cm -1 、1379cm -1 and 1536cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0116] In preferred embodiments, the free base of the invention is amorphous and:
[0117] (a) has an FT Raman spectrum with a peak at about 335 cm -1 、415cm -1 、544cm -1 、641cm -1 、684cm -1 、759cm -1 、801cm -1 、845cm -1 、879cm -1 、910cm -1 、1011cm -1 、1061cm-1 、1077cm -1 、1137cm -1 、1203cm -1 、1296cm -1 、1359cm -1 、1386cm -1 、1438cm -1 、1556cm -1 、1579cm -1 、1608cm -1 、2862cm -1 、2927cm -1 and 3060cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or
[0118] (b) has an ATR-FTIR spectrum with a peak at about 679 cm -1 、716cm -1 、742cm -1 、778cm -1 、842cm -1 、869cm -1 、928cm -1 、1010cm -1 、1043cm -1 、1078cm -1 、1127cm -1 、1182cm -1 、1224cm -1 、1285cm -1 、1379cm -1 、1455cm -1 、1537cm -1 、1589cm -1 、1632cm -1 、2863cm -1 、2926cm -1 、3047cm -1 and 3255cm -1 ±2cm -1 The absorption band is included at the wave number of .
[0119] In particularly preferred embodiments, the free base of the invention is amorphous and:
[0120] (a) Having Fig. 9 substantially the same FT Raman spectrum as shown; and / or
[0121] (b) Having Fig.17Essentially the same ATR-FTIR spectra are shown.
[0122] In one embodiment, the free base of the invention is crystalline and has wavelengths at 6.93, 7.28, 12.11, 14.52, 15.04, 15.73, 19.44 and 22.00 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
[0123] In preferred embodiments, the free base of the invention is crystalline and has a relative humidity of 6.93, 7.28, 8.07, 10.08, 12.11, 13.53, 13.92, 14.52, 15.04, 15.73, 16.21, 16.96, 17.57, 18.13, 18.46, 19.31, 19.44, 19.87, 20.25, 20. .51, 20.97, 22.00, 22.29, 22.49, 22.93, 23.12, 23.33, 23.60, 24.03, 24.40, 24.92, 25.04, 25.26, 25.62, 25.86, 26.15, 26.52, 27.26, 28.66, and 30.58 [°2θ ± 0.2°2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
[0124] In particularly preferred embodiments, the free base of the invention is crystalline and has Fig.18 Substantially the same X-ray powder diffraction (XRPD) pattern is shown.
[0125] Preparation of crystalline forms
[0126] In one aspect, the invention provides methods of preparing the crystalline and amorphous forms described herein, wherein the methods are as outlined in the Examples. It should be noted that the solvents, temperatures and other reaction conditions presented in the Examples may vary.
[0127] In another aspect, the invention provides crystalline and amorphous forms described herein when obtained by the methods described in the Examples.
[0128] Suitable solvent
[0129] The therapeutic agent that can be used in mammals (such as humans) must be prepared according to management guidelines. Such government-mandated guidelines are called good manufacturing practices (GMP). The GMP guidelines outline the acceptable contamination levels of active therapeutic agents, such as the amount of residual solvents in the final product. Preferred solvents are those solvents that are suitable for GMP equipment and meet industrial safety considerations. The categories of solvents are defined in, for example, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), "Impurities: Guidelines for Residual Solvents, " Q3C (R3), (November 2005).
[0130] Solvents are divided into three categories. Class 1 solvents are toxic and should be avoided. Class 2 solvents are solvents that have limited use in the manufacturing process of therapeutic agents. Class 3 solvents are solvents that have low toxic potential and pose a low risk to human health. Data for Class 3 solvents have shown low toxicity in acute or short-term studies and are negative in genotoxicity studies.
[0131] Class 1 solvents that should be avoided include: benzene; carbon tetrachloride; 1,2-dichloroethane; 1,1-dichloroethylene; and 1,1,1-trichloroethane.
[0132] Examples of Class 2 solvents are acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethylene, dichloromethane, 1,2-dimethoxyethane, N,N-dimethylacetamide, N,N-dimethylformamide, 1,4-dioxane, 2-ethoxyethanol, ethylene glycol, formamide, hexane, methanol, 2-methoxyethanol, methyl butyl ketone, methylcyclohexane, N-methylpyrrolidine, nitromethane, pyridine, sulfolane, tetralin, toluene, 1,1,2-trichloroethylene and xylene.
[0133] Three types of solvents with low toxicity include: acetic acid, acetone, anisole, 1-butanol, 2-butanol, butyl acetate, tert-butyl methyl ether (MTBE), isopropylbenzene, dimethyl sulfoxide, ethanol, ethyl acetate, ethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate and tetrahydrofuran.
[0134] In some embodiments, the compositions comprising the crystalline and amorphous forms described herein include residual amounts of organic solvents. In some embodiments, the compositions comprising the crystalline and amorphous forms described herein include detectable amounts of organic solvents. In some embodiments, the compositions comprising the crystalline and amorphous forms described herein include residual amounts of Class 3 solvents. In some embodiments, Class 3 solvents are selected from the group consisting of acetic acid, acetone, anisole, 1-butanol, 2-butanol, butyl acetate, tert-butyl methyl ether, isopropylbenzene, dimethyl sulfoxide, ethanol, ethyl acetate, ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, and tetrahydrofuran. In some embodiments, the Class 3 solvent is selected from the group consisting of: 1-butanol, 2-butanol, ethanol, 3-methyl-1-butanol, 2-methyl-1-propanol, 1-pentanol, 1-propanol, and 2-propanol. In some embodiments, the Class 3 solvent is ethanol or 1-propanol.
[0135] The methods and compositions described herein include the use of the crystalline and amorphous forms described herein. In addition, the crystalline and amorphous forms described herein may exist in unsolvated forms as well as solvated forms with pharmaceutically acceptable solvents such as water, 1-propanol, ethanol, and the like.
[0136] Pharmaceutical compositions / formulations
[0137] Pharmaceutical compositions are prepared in a conventional manner using one or more physiologically acceptable carriers (including excipients and auxiliaries) that facilitate processing of the active compounds into pharmaceutically acceptable preparations. Suitable techniques, carriers and excipients include those found in, for example, Remington: The Science and Practice of Pharmacy, 19th Edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition (Lippincott Williams & Wilkins 1999), which are incorporated herein by reference in their entirety.
[0138] In one aspect, the present invention relates to a pharmaceutical composition comprising any one of the crystalline and amorphous forms described herein or a mixture thereof, and at least one additional ingredient selected from pharmaceutically acceptable carriers, diluents and excipients.
[0139] In some embodiments, the crystalline or amorphous forms described herein are formulated for intravenous administration to a mammal.
[0140] In one aspect, the present invention provides a solution for intravenous administration to a mammal, the solution comprising:
[0141] (i) any of the crystalline and amorphous forms described herein, or mixtures thereof;
[0142] (ii) water for injection; and
[0143] (iii) Sodium chloride.
[0144] In one embodiment, the concentration of the crystalline and amorphous forms described herein or a mixture thereof in the solution for intravenous administration according to the present invention is 50 mg / mL.
[0145] Contemplated pharmaceutical compositions provide therapeutically effective amounts of the crystalline and amorphous forms described herein, enabling administration, for example, once a day, twice a day, three times a day, etc. In one embodiment, the pharmaceutical compositions provide effective amounts of the crystalline and amorphous forms described herein, enabling administration once a day.
[0146] In one embodiment, the pharmaceutical compositions described herein are used for therapeutic treatment. In therapeutic applications, the composition is administered to a patient already suffering from a disease or condition in an amount sufficient to cure or at least partially prevent at least one symptom of the disease or condition. In certain embodiments, the effective amount for this purpose depends on the severity and course of the disease or condition, previous therapy, the patient's health, weight, and response to the drug and / or the judgment of the treating physician.
[0147] Use of the crystalline and amorphous forms of the present invention
[0148] The compounds described herein possess valuable pharmacological properties for the treatment or prevention of infections caused by pathogens, in particular by bacteria, more in particular by Acinetobacter species, most in particular by Acinetobacter baumannii, and diseases caused thereby, in particular bacteremia, pneumonia, meningitis, urinary tract infections and wound infections.
[0149] In one aspect, the invention provides a compound as described herein for use as a medicament.
[0150] In one embodiment, the drug is an antibiotic.
[0151] In one aspect, the present invention provides a method for treating bacterial infections and diseases caused thereby in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound described herein.
[0152] In one aspect, the present invention provides a compound as described herein for use in the treatment of bacterial infections and diseases caused thereby in mammals.
[0153] In one aspect, the present invention provides the use of the compounds described herein for treating bacterial infections and diseases caused thereby in mammals.
[0154] In one aspect, the present invention provides the use of a compound as described herein in the manufacture of a medicament for treating bacterial infections and diseases caused thereby in mammals.
[0155] In one embodiment, the disease caused thereby is selected from bacteremia, pneumonia, meningitis, urinary tract infection and wound infection.
[0156] In one embodiment, the bacterial infection is selected from Gram-negative bacterial infection.
[0157] In one embodiment, the bacterial infection is selected from "ESKAPE" pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species & E. coli) infection, or a combination thereof.
[0158] In one embodiment, the bacterial infection is a nosocomial infection.
[0159] In one embodiment, the bacterial infection is selected from multi-drug resistant (MDR) bacterial infection, in particular MDR Acinetobacter baumannii (A. baumanniii) infection.
[0160] In one embodiment, the bacterial infection is selected from carbapenem-resistant bacterial infection, in particular carbapenem-resistant Acinetobacter baumannii infection.
[0161] In one embodiment, the bacterial infection is selected from Acinetobacter species, most particularly Acinetobacter baumannii infection.
[0162] Combination therapy
[0163] Crystallization and amorphous forms as described herein can be used alone or in combination with other therapeutic agents. For example, the second agent of the drug combination formulation or dosage regimen may have an activity complementary to the crystallization and amorphous forms as described herein, so that they do not produce adverse effects on each other. The compound can be applied together or separately in a single pharmaceutical composition. In one embodiment, crystallization and amorphous forms as described herein can be co-applied with antibiotics, particularly co-applied with antibiotics to treat or prevent infections caused by Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter or Escherichia coli or a combination thereof and diseases caused therefrom.
[0164] The term "co-administration" refers to the simultaneous administration of the crystalline and amorphous forms as described herein with another one or more active pharmaceutical ingredients (particularly antibiotic agents) or any manner of separate sequential administration. If the administration is not simultaneous, the compounds should be administered at a time close to each other. In addition, it does not matter whether the compounds are administered in the same dosage form, for example, one compound can be administered intravenously and another compound can be administered orally.
[0165] Generally, any agent with antimicrobial activity can be co-administered. Specific examples of such agents are carbapenems (meropenem), fluoroquinolones (Ciprofloxacin), aminoglycosides (amikacin), tetracyclines (tigecycline), colistin, sulbactam, sulbactam + dulobactam, cefoperazone (Fetroja), and macrolides (erythromycin).
[0166] In one aspect, the present invention provides a pharmaceutical composition as described herein, further comprising an additional therapeutic agent.
[0167] In one aspect, the present invention provides a pharmaceutical combination comprising the crystalline and amorphous forms described herein and an additional therapeutic agent.
[0168] In one embodiment, the additional therapeutic agent is an antibiotic.
[0169] In one embodiment, the additional therapeutic agent is an antibiotic agent, which can be used to treat or prevent infections caused by Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter or Escherichia coli or a combination thereof and diseases caused thereby.
[0170] In one embodiment, the additional therapeutic agent is an antibiotic agent selected from the group consisting of carbapenem (meropenem), fluoroquinolone (ciprofloxacin), aminoglycoside (amikacin), tetracycline (tigecycline), colistin, sulbactam, sulbactam + dulobactam, cefiderocol (Fetroja), and macrolide (erythromycin).
[0171] Examples
[0172] The following examples are provided to illustrate the present invention. They should not be considered as limiting the scope of the invention, but are merely representative.
[0173] abbreviation
[0174] The following abbreviations are used in this patent specification:
[0175] ATR reduces total reflection
[0176] FT Fourier transform
[0177] IR
[0178] XRPD X-ray powder diffraction
[0179] Example 1 - Preparation of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid ("free base")
[0180] 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid tetrakis(trifluoroacetate) salt (described in WO2019206853, 5.19 g, 4.2 mmol) was dissolved in water (60 mL) and acetonitrile (120 mL). Aqueous NaOH 32% (1.88 g) was added. Aqueous 1 M NaOH was added to the solution until pH = 9.8 was reached (about 2 g). After a few hours, a suspension was formed, which was stirred at room temperature for another 1.5 hours. The precipitate was filtered off, washed with water and dried under reduced pressure at 40° C. to give 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (1.90 g, 59%) as a white powder.
[0181] MS: 791.37[M+H + ]
[0182] Example 2 - Preparation of Amorphous 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid monohydrochloride ("HCl salt")
[0183] 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (48.7 g, 61.6 mmol) was suspended in water (500 mL) and the pH was brought to 7.0 by adding a mixture of aqueous HCl 25% (9.04 g) and water (51.2 mL). The solution was passed through 3M TM ZETA PLUS TM Filtered and then passed through a 0.2 μm The obtained clear solution was spray dried and dried under vacuum to obtain white powder (amorphous form) 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid monohydrochloride (38.8 g, 76%).
[0184] MS: 791.37[M+H + ]
[0185] Example 3 - Preparation of Crystalline Form A1 of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid monohydrochloride
[0186] 200mg amorphous HCl salt (Example 2) is dissolved in 0.5mL water at 23°C while stirring to form a highly viscous solution. Once solid particles are no longer visible, acetonitrile is added dropwise to the solution. Rapidly disappearing white turbidity (tiny oil droplets form these turbidities) is observed in the solution. More acetonitrile is added until the turbidity no longer disappears, to adjust very slight supersaturation. The seed crystals of the crystalline free alkali (Form A1) are added to the solution with a spatula tip. The seed crystals are observed to be not dissolved by the naked eye. The mixture is stirred at 22.5°C for 12 hours with 200rpm. The solid matter is separated from the liquid and identified as a crystalline material by an optical microscope. The material is subsequently filtered and dried 14 hours at room temperature (22.5°C) under reduced pressure (20mbar). The white powder is characterized as crystalline form A1 by XRPD.
[0187] For larger scale, 50.46g amorphous HCl salt (Example 2) was dissolved in 85mL water at 23°C while stirring. Once solid particles were no longer visible, 150mL acetonitrile was slowly added. After about 50mL, the HCl salt began to oil out. The emulsion was stirred for about 30 minutes until spontaneous crystallization of the oil phase was observed. Another 50mL acetonitrile was added to keep a stirrable suspension. The suspension was stirred for 24 hours. After filtration, the white powder was dried at reduced pressure (20mbar) and room temperature (23°C) for 14 hours. The resulting solid was identified as pure form A1 by XRPD.
[0188] Example 4 - Preparation of Crystalline Form A2 of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid monohydrochloride
[0189] 100mg amorphous HCl salt (Example 2) was dissolved in 0.25mL water at 23°C while stirring to form a highly viscous solution. Once the solid particles were no longer visible, crystalline form A1 seed crystals (Example 3) were added with a spatula tip. The seed crystals were observed to be not dissolved by naked eye. The mixture was stirred at 200rpm for 12 hours at 23°C. A white suspension was subsequently observed. The material was filtered and dried at room temperature (23°C) under reduced pressure (20mbar) for 14 hours. The white powder was characterized as crystalline form A2 by XRPD, Raman and IR, which is isostructural with crystalline form A1.
[0190] For a larger scale, 2.02g of amorphous HCl salt (Example 2) was dissolved in 3.00mL water at 23°C and stirred for 14 hours. The solution with extremely high viscosity was heated to 35°C. Seed crystals of Form A2 were added and dissolved rapidly. The solution was cooled to 2°C overnight. The viscosity was too high to stir the clear honey-like solution. A temperature cycle between 10°C and 35°C was started, and the sample was placed under stirring at 200rpm for 7 days. A white suspension was observed. The mixture was cooled to 5°C and stirred at this temperature overnight. The solid was filtered and dried for 6 hours under ambient air (31% rH, 22°C). The white powder was characterized as pure Form A2 by XRPD.
[0191] Example 5 - Preparation of Crystalline Form "Pattern 4" of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid monohydrochloride
[0192] Pattern 4 was observed by drying Form A2 (Example 4) at 50°C and 5 mbar for 24 hours.
[0193] Example 6 - Preparation of Crystalline Form "Pattern 5" of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid monohydrochloride
[0194] Pattern 5 was observed by grinding Form A1 (Example 3) in acetonitrile with glass beads in a vial on a vortex mixer.
[0195] Example 7 - Preparation of Amorphous 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid
[0196] In a 1000ml round-bottom flask, 11.0g amorphous HCl salt (Example 2), 323.5ml acetone and 161.8ml water were added at room temperature. The mixture was stirred. NaOH 0.1M was added dropwise to the orange mixture at room temperature until a pH of 9.80 was reached. 145ml of 0.1M sodium hydroxide was consumed. The solvent was evaporated as much as possible on a rotary evaporator. The remainder was deep frozen with dry ice and then freeze-dried to obtain the title compound (Pd contamination: 3261ppm, Cl-contamination (from NaCl): 4.2% wt / wt). Example 8 - Preparation of Crystalline Form A1 of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid
[0197] 44.21g amorphous HCl salt (Example 2) is suspended in 260.2mL water and 71.88mL acetonitrile at room temperature. 27.61mL HCl (0.214mol, 4eq) is added to the white suspension. The white suspension becomes a light yellow turbid solution. After being heated to 40 ° C, the solution becomes clear. At room temperature, a mixture consisting of 20.15mL water and 20.15mL NaOH (0.218mol, 4.07eq) is added, and the pH is adjusted to about neutral pH (pH 7.19). Optionally, the solution is inoculated with free alkali (Form A family, 10.4mg). Then, the pH of the solution is adjusted to pH 9.8 by adding 54.9g 1N NaOH. The colorless solution becomes more and more turbid from pH 9.1. The resulting suspension is stirred at room temperature for one hour, and then filtered. The crystals were dried overnight at 65°C / 2 mbar and dried in a vacuum oven at 25°C to give 41.82 g of pure Form A1. It was found that the free base can also exist as an isostructural mixed solvate / hydrate crystalline system containing various organic solvents and water in the crystal lattice, which is not described here. For example, such isostructural crystalline forms can be obtained from solvent mixtures consisting of water and ethanol, or water in propanol.
[0198] Example 9 - Preparation of Crystalline Form B of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid
[0199] 19.775 g of amorphous HCl salt (Example 2) was added to a mixture of 100 mL of water and 15.56 mL of 1-PrOH and dissolved at 35 ° C under stirring. The pH of the solution was set to 9.2 by adding 50 mL of 8 wt.% aqueous NaOH, and 135 mg of ABX free base seed crystals were added as a suspension in 1 g of water and 1 g of 1-PrOH. The resulting suspension was aged for 60 minutes. Thereafter, the pH was increased to 9.8 by adding 75 mL of 1 wt.% aqueous NaOH over 1 hour. The suspension was aged for 15 minutes, and the temperature was reduced to 20 ° C within 1 hour. After aging for another 15 minutes, the suspension was filtered, the solid was washed with water, and the sample was characterized as pure crystalline form A3 by XRPD. The remaining material was dried at 80 ° C and 20 mbar for 16 hours. The resulting white powder was characterized as pure crystalline form B by XRPD.
[0200] Example 10 - Alternative Preparation of Crystalline Form B of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid
[0201] 1.7 g of amorphous free base (Example 7) was weighed into a 40 mL magnifying glass and 20 mL of solvent (15% water v / v in propanol) was added under stirring (350 rpm). A viscous red film was formed at the bottom. Subsequently, the solution was heated to 80 ° C, whereby the reddish substance did not dissolve. The hot solution was filtered through a 0.2 μm Satorius Nutsche filter. The filtrate became turbid and was heated to 80 ° C again. Without stirring, the yellow solution was cooled from 80 ° C to 10 ° C in 8 hours. The yellow oil was retained and inoculated with Form A at 25 ° C with a spatula tip under stirring (350 rpm). The white suspension was filtered through a Satorius Nutsche 0.2um filter. The filter cake was washed with 3x 10 mL of fresh solvent and then dried overnight at 50 ° C / 5 mbar. (Off-white, crystalline solid, Pd contamination: 2048 ppm, Cl – Contamination (from NaCl): 0.1% wt / wt).
[0202] Example 11 - Preparation of Crystalline Form "Pattern 10.1" of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosyl-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid
[0203] 1 g of Form B free base was weighed into a 7.5 mL magnifying glass and 5 mL of solvent (5% water v / v in ethanol) was added at 20°C under stirring (100 rpm). After 2 days, the white suspension was centrifuged at 5000 rpm. The resulting white wet powder was characterized by XRPD as pure crystalline pattern 10.1. Example 12 - ATR FTIR
[0204] Experimental methods
[0205] ATR-FTIR spectra were recorded using a ThermoNicolet iS5 FTIR spectrometer with ATR auxiliary without any sample preparation. The spectral range was 4000 cm -1 With 650cm -1 The resolution is 2cm -1, and 50 co-added scans were collected (except for the spectrum of Form A1 of the HCl salt, where 32 co-added scans were collected). Happ-Genzel apodization was applied. The use of ATR FTIR will result in the relative intensities of the infrared bands being different from those seen in the transmission FTIR spectra obtained using KBr disks or paraffin paste sample preparations. Due to the nature of ATR FTIR, bands at lower wavenumbers are more intense than bands at higher wavenumbers.
[0206] result
[0207] The crystalline form A1, crystalline form A2 and amorphous form of the monohydrochloride salt of formula (I), and the crystalline form A1, crystalline form B and amorphous form of the free base of formula (Ia) were characterized by ATR FTIR as described above. The unique ATR FTIR peaks are presented in Tables 1 to 6. The characteristic ATR FTIR spectra are shown in Figure 3 , 6 , 10, 13, 16 and 17.
[0208] Table 1
[0209]
[0210] Table 2
[0211]
[0212] Table 3
[0213]
[0214] Table 4
[0215]
[0216]
[0217] Table 5
[0218]
[0219] Table 6
[0220]
[0221] Example 13 – Raman spectroscopy
[0222] Experimental methods
[0223] FT-Raman spectra were recorded using a Bruker MultiRam FT-Raman spectrometer equipped with a liquid nitrogen-cooled germanium detector and a 1064 nm NdYAG laser without any sample preparation. The spectral range was 4000 cm -1 With 100cm -1 The resolution is 2cm -1 (Except the spectrum of the HCl salt form A1: 4 cm -1 ), and 2048 co-added scans were collected (except for the spectrum of Form B of the free base: 1024 scans). The laser power was set to 300 mW (except for the spectrum of Form A1 of the HCl salt: 100 mW), and Blackman-Harris 4-Term apodization was applied.
[0224] result
[0225] The crystalline form A1, crystalline form A2 and amorphous form of the monohydrochloride salt of formula (I), and the crystalline form A1, crystalline form B and amorphous form of the free base of formula (Ia) were characterized by FT Raman spectroscopy as described above. The unique FT-Raman peaks are presented in Tables 7 to 11. The characteristic FT Raman spectra are shown in Figure 2 , 5 , 9, 12 and 15. It should be noted that the amorphous form of the free base and the HCl salt cannot be distinguished by Raman spectroscopy.
[0226] Table 7
[0227]
[0228] Table 8
[0229]
[0230] Table 9
[0231]
[0232]
[0233] Table 10
[0234]
[0235] Table 11
[0236]
[0237] Example 14 - XRPD
[0238] Experimental methods
[0239] The diffractometer was used under ambient conditions with a STOE STADIP diffractometer (Cu Kα radiation). X-ray diffraction patterns were recorded in transmission geometry with a primary Ge-monochromator, Mythen 1K silicon strip detector, angular range 3° to 42° 2θ, 20 s measurement time per step). The material was prepared and analyzed without further processing (eg grinding or sieving).
[0240] The measurement and evaluation of X-ray diffraction data were performed using WinXPOW software (STOE&Cie GmbH, Darmstadt, Germany).
[0241] result
[0242] Crystalline Form A1, Crystalline Form A2, Pattern 4 and Pattern 5 of the monohydrochloride salt of Formula (I), and Crystalline Form A1 and Crystalline Form B of the free base of Formula (Ia) were characterized by XRPD as described above. The unique XRPD peaks of the crystalline forms are presented in Tables 12 to 17. The characteristic XRPD diffraction patterns of the crystalline forms are shown in Figure 1 , 4 , 7, 8, 11 and 14.
[0243] Table 12 - Free base crystalline form A1
[0244]
[0245] Table 13 - Free Base Crystalline Form B
[0246]
[0247] Table 14 - HCl Salt Crystalline Form A1
[0248]
[0249] Table 15 - HCl Salt Crystalline Form A2
[0250]
[0251] Table 16 – HCl Salt Crystallization “Mode 4”
[0252]
[0253] Table 17 – HCl Salt Crystallization “Mode 5”
[0254]
[0255]
[0256] Table 18 – Free base “Pattern 10.1”
[0257]
[0258] Example 15 - Solubility Assessment
[0259] Experimental methods
[0260] Approximately 1 g of material was equilibrated in 8.5 mL of water at 20°C for 2 days. 1 mL of the suspension was centrifuged. The filtrate was analyzed by uPLC.
[0261] result
[0262] Form A family free zwitterions <1mg / mL Form A Family HCl Salt 123.5mg / mL Amorphous HCl salt 177.6mg / mL
Claims
1. A monohydrochloride salt of 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (Formula I) 2. A 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (Formula Ia), The 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid is in a zwitterionic state 3. 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid according to claim 2, which is in crystalline form.
4. The crystalline form according to claim 3, That: (a) has an X-ray powder diffraction (XRPD) pattern with chromatic aberrations at 6.6, 9.0, 9.9, 10.1, 11.8, 12.0, 14.5, 15.4 [°2θ±0.2°2θ, Cu Kα radiation ] includes a peak; and / or (b) has an FT Raman spectrum with a peak at about 757 cm -1 、1290cm -1 、1433cm -1 and 1548cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (c) has an ATR-FTIR spectrum with a peak at about 745 cm -1 、1367cm -1 、1533cm -1 and 1638cm -1 ±2cm -1 The absorption band is included at the wave number of .
5. The crystalline form according to claim 4, That: (a) having an X-ray powder diffraction (XRPD) pattern having wavelengths at 6.6, 9.0, 9.9, 10.1, 11.8, 12.0, 14.5, 14.8, 15.4, 15.7, 16.0, 16.4, 16.7, 17.0, 17.8, 18.0, 18.4, 18.7, 19.1, 19.6, 20.0, 20.4, 20.7, 20.9, 21.2, 21.5, 22.1, 23.3, 23.8, 24.2, 24.6, 24.9 and 25.7 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes a peak; and / or (b) has an FT Raman spectrum with a peak at about 233 cm -1 、331cm -1 、352cm -1 、414cm -1 、462cm -1 、543cm -1 、574cm -1 、596cm -1 、614cm -1 、625cm -1 、641cm -1 、682cm -1 、696cm -1 、718cm -1 、757cm -1 、839cm -1 、878cm -1 、947cm -1 、1010cm -1 、1044cm -1 、1059cm -1 、1075cm -1 、1097cm -1 、1136cm -1 、1149cm -1 、1179cm -1 、1203cm -1 、1234cm -1 、1290cm -1 、1303cm -1 、1361cm -1 、1372cm -1 、1433cm -1 、1453cm -1 、1491cm -1 、1547cm -1 、1557cm -1 、1576cm -1 、1610cm -1 、1660cm -1 、2868cm -1 、2930cm -1 、3059cm -1 and 3113cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (c) has an ATR-FTIR spectrum with a peak at about 677 cm -1 、716cm -1 、745cm -1 、771cm -1 、784cm -1 、801cm -1 、839cm -1 、868cm -1 、906cm -1 、927cm -1 、967cm -1 、1014cm -1 、1043cm -1 、1077cm -1 、1125cm -1 、1171cm -1 、1213cm -1 、1243cm -1 、1283cm -1 、1301cm -1 、1367cm -1 、1399cm -1 、1431cm -1 、1456cm -1 、1471cm -1 、1533cm -1 、1590cm -1 、1638cm -1 、1658cm -1 、1694cm -1 、2862cm -1 、2925cm -1 、3029cm -1 and 3212cm -1 ±2cm -1 The absorption band is included at the wave number of .
6. The crystalline form according to claim 5, That: (a) having an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 14; and / or (b) having a FT Raman spectrum substantially the same as that shown in FIG. 15 ; and / or (c) has substantially the same ATR-FTIR spectrum as that shown in FIG. 16 .
7. The monohydrochloride salt according to claim 1, which is crystalline and has a relative humidity of 5.16, 7.94, 9.98, 10.46, 10.78, 11.66, 17.28 and 18.90 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
8. The crystalline monohydrochloride according to claim 7, That: (a) has an X-ray powder diffraction (XRPD) pattern with chromatic aberrations at 5.16, 7.94, 9.98, 10.46, 10.78, 11.66, 15.52, 15.70, 17.28 and 18.90 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes a peak; and / or (b) has an FT Raman spectrum with a peak at about 103 cm -1 、1390cm -1 、2246cm -1 and 2930cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (c) has an ATR-FTIR spectrum with a peak at about 752 cm -1 、1386cm -1 、1534cm -1 and 1602cm -1 ±2cm -1 The wavenumbers include absorption bands.
9. The crystalline monohydrochloride according to claim 8, That: (a) has an X-ray powder diffraction (XRPD) pattern with peaks at 5.16, 6.54, 7.94, 9.98, 10.46, 10.78, 11.54, 11.66, 11.98, 12.10, 13.02, 13.16, 14.38, 14.82, 15.04, 15.52, 15.70, 15.94, 16.74, 17.28, 17.74, 18.10, 18.32, 18.78, 18.90, 19.72, 20. 02, 20.28, 20.80, 20.96, 21.16, 21.56, 21.62, 22.38, 22.66, 23.28, 23.50, 23.98, 24.72, 24.92, 25.20, 25.60, 25.98, 26.22, 26.98, 27.20, 27.42, 27.88, 28.10, 28.48, 28.66, 29.00, 29.70, and 30.00 [°2θ ± 0.2°2θ, Cu Kα radiation ] includes a peak; and / or (b) has an FT Raman spectrum with a peak at about 103 cm -1 、137cm -1 、225cm -1 、279cm -1 、330cm -1 、382cm -1 、416cm -1 、449cm -1 、479cm -1 、517cm -1 、547cm -1 、563cm -1 、596cm -1 、624cm -1 、639cm -1 、685cm -1 、758cm -1 、790cm -1 、807cm -1 、848cm -1 、878cm -1 、898cm -1 、955cm -1 、1011cm -1 、1059cm -1 、1074cm -1 、1140cm -1 、1183cm -1 、1203cm -1 、1247cm -1 、1288cm -1 、1316cm -1 、1334cm -1 、1358cm -1 、1391cm -1 、1425cm -1 、1435cm -1 、1451cm -1 、1489cm -1 、1557cm -1 、1580cm -1 、1605cm -1 、1666cm -1 、2246cm -1 、2859cm -1 、2930cm -1 、2985cm -1 、3063cm -1 and 3116cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (c) has an ATR-FTIR spectrum with a peak at about 659 cm -1 、717cm -1 、731cm -1 、752cm -1 、778cm -1 、786cm -1 、803cm -1 、847cm -1 、874cm -1 、887cm -1 、906cm -1 、931cm -1 、950cm -1 、971cm -1 、1010cm -1 、1017cm -1 、1080cm -1 、1098cm -1 、1134cm -1 、1148cm -1 、1180cm -1 、1215cm -1 、1248cm -1 、1282cm -1 、1334cm -1 、1385cm -1 、1439cm -1 、1459cm -1 、1534cm -1 、1602cm -1 、1659cm -1 、1682cm -1 、2936cm -1 、3054cm -1 、3239cm -1 and 3434cm -1 ±2cm -1 The absorption band is included at the wave number of .
10. The crystalline monohydrochloride salt according to claim 9, That: (a) having an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 1; and / or (b) having a FT Raman spectrum substantially the same as that shown in FIG. 2 ; and / or (c) has substantially the same ATR-FTIR spectrum as shown in FIG3 .
11. The crystalline monohydrochloride salt according to claim 7, That: (a) has an X-ray powder diffraction (XRPD) pattern with chromatic aberrations at 5.20, 7.94, 9.92, 10.36, 10.68, 11.60, 15.58, 17.16 and 18.78 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes a peak; and / or (b) has an FT Raman spectrum with a peak at about 163 cm -1 、1391cm -1 、2920cm -1 and 2948cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (c) has an ATR-FTIR spectrum with a peak at about 753 cm -1 、1387cm -1 、1541cm -1 、1604cm -1 ±2cm -1 The absorption band is included at the wave number of .
12. The crystalline monohydrochloride salt according to claim 11, That: (a) has an X-ray powder diffraction (XRPD) pattern with peaks at 5.20, 6.52, 7.94, 9.92, 10.36, 10.68, 11.60, 12.04, 13.02, 13.10, 14.34, 14.70, 14.92, 15.58, 15.94, 16.68, 17.16, 17.52, 17.82, 18.06, 18.22, 18.78, 19.70, 19.80, 19.96, 20.64, 20. 88, 21.10, 21.50, 22.30, 22.58, 23.18, 23.44, 23.58, 23.94, 24.22, 24.70, 25.02, 25.42, 25.74, 26.18, 26.82, 27.04, 27.24, 27.72, 27.90, 28.34, 28.86, 29.10, 29.52, 29.74, 30.14, 31.08, and 31.52 [°2θ ± 0.2°2θ, Cu Kα radiation ] includes a peak; and / or (b) has an FT Raman spectrum with a peak at about 107 cm -1 、135cm -1 、163cm -1 、225cm -1 、336cm -1 、417cm -1 、450cm -1 、480cm -1 、518cm -1 、546cm -1 、562cm -1 、596cm -1 、621cm -1 、639cm -1 、686cm -1 、758cm -1 、774cm -1 、790cm -1 、813cm -1 、848cm -1 、877cm -1 、899cm -1 、955cm -1 、1011cm -1 、1046cm -1 、1059cm -1 、1075cm -1 、1140cm -1 、1188cm -1 、1200cm -1 、1234cm -1 、1249cm -1 、1289cm -1 、1317cm -1 、1335cm -1 、1358cm -1 、1391cm -1 、1426cm -1 、1435cm -1 、1452cm -1 、1489cm -1 、1558cm -1 、1578cm -1 、1606cm -1 、1660cm -1 、2920cm -1 、2948cm -1 、2986cm -1 and 3059cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (c) has an ATR-FTIR spectrum with a peak at about 673 cm -1 、718cm -1 、739cm -1 、753cm -1 、773cm -1 、779cm -1 、803cm -1 、848cm -1 、875cm -1 、888cm -1 、898cm -1 、906cm -1 、932cm -1 、946cm -1 、971cm -1 、1010cm -1 、1017cm -1 、1037cm -1 、1067cm -1 、1082cm -1 、1095cm -1 、1134cm -1 、1149cm -1 、1169cm -1 、1181cm -1 、1223cm -1 、1248cm -1 、1286cm -1 、1333cm -1 、1387cm -1 、1406cm -1 、1424cm -1 、1440cm -1 、1459cm -1 、1467cm -1 、1541cm -1 、1585cm -1 、1604cm -1 、1658cm -1 、2937cm -1 、3054cm -1 、3230cm -1 、3349cm -1 and 3429cm -1 ±2cm -1 The wavenumbers include absorption bands.
13. The crystalline monohydrochloride salt according to claim 12, That: (a) having an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 4; and / or (b) having a FT Raman spectrum substantially the same as that shown in FIG5 ; and / or (c) has substantially the same ATR-FTIR spectrum as shown in FIG6 .
14. The crystalline monohydrochloride salt of claim 7 having wavelengths of 5.6, 7.14, 8.66, 9.92, 10.52, 10.88, 11.92, 15.6, 16.64, 17.7 and 20.94 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
15. The crystalline monohydrochloride salt of claim 14, having an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 7.
16. The crystalline monohydrochloride salt of claim 7 having wavelengths of 5.22, 8.16, 9.88, 10.04, 10.48, 10.8, 11.48, 11.72, 12.2, 12.58, 13.1, 13.62, 14.5, 14.82, 15.12, 15.7, 16.02, 17.02, 17.82, 18.16, 18.42, 18.58, 18.72, 18.9, 19.4, 19.62 and 19.84 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
17. The crystalline monohydrochloride salt of claim 14, having an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in FIG8.
18. The monohydrochloride salt according to claim 1, which is amorphous and (a) has an FT Raman spectrum with a peak at about 1296 cm -1 、1608cm -1 、2928cm -1 and 3060cm -1 ±2cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (b) has an ATR-FTIR spectrum with a peak at about 742 cm -1 、778cm -1 、1377cm -1 and 1531cm -1 ±2cm -1 The wavenumbers include absorption bands.
19. The amorphous monohydrochloride according to claim 18, (a) has an FT Raman spectrum with a peak at about 334 cm -1 、415cm -1 、543cm -1 、641cm -1 、683cm -1 、759cm -1 、803cm -1 、842cm -1 、879cm -1 、912cm -1 、1011cm -1 、1061cm -1 、1077cm -1 、1137cm -1 、1203cm -1 、1296cm -1 、1359cm -1 、1381cm -1 、1437cm -1 、1453cm -1 、1557cm -1 、1579cm -1 、1609cm -1 、2928cm -1 and 3059cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (b) has an ATR-FTIR spectrum with a peak at about 680 cm -1 、716cm -1 、742cm -1 、778cm -1 、841cm -1 、868cm -1 、1010cm -1 、1043cm -1 、1078cm -1 、1129cm -1 、1177cm -1 、1224cm -1 、1285cm -1 、1376cm -1 、1403cm -1 、1456cm -1 、1531cm -1 、1582cm -1 、1627cm -1 、2924cm -1 and 3243cm -1 ±2cm -1 The absorption band is included at the wave number of .
20. The amorphous monohydrochloride according to claim 19, That: (a) having substantially the same FT Raman spectrum as that shown in FIG. 9 ; and / or (b) has substantially the same ATR-FTIR spectrum as that shown in FIG. 10 .
21. The crystalline form according to claim 3, That: (a) has an X-ray powder diffraction (XRPD) pattern with chromatic aberrations at 5.46, 8.08, 10.36, 11.56, 11.86, 16.56 and 17.44 [°2θ±0.2°2θ, Cu Kα radiation ] includes a peak; and / or (b) has an FT Raman spectrum with a peak at about 838 cm -1 、1079cm -1 、1373cm -1 and 1608cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (c) has an ATR-FTIR spectrum with a peak at about 746 cm -1 、784cm -1 、1371cm -1 and 3437cm -1 ±2cm -1 The wavenumbers include absorption bands.
22. The crystalline form according to claim 21, That: (a) has an X-ray powder diffraction (XRPD) pattern with peaks at 5.46, 8.08, 9.90, 10.36, 11.56, 11.86, 12.46, 12.84, 13.36, 13.70, 13.86, 14.82, 14.98, 15.28, 16.56, 17.00, 17.44, 17.72, 18.18, 18.42, 18.64, 18.94, 19.26, 19.80, 20.12, 20. 52, 20.78, 21.02, 21.14, 21.34, 21.48, 21.66, 21.80, 22.74, 22.84, 23.22, 23.42, 23.72, 24.02, 24.42, 24.58, 25.10, 25.52, 25.92, 26.18, 26.96, 27.60, 27.82, 27.94, 28.64, 29.16, and 29.92 [°2θ ± 0.2°2θ, Cu Kα radiation ] includes a peak; and / or (b) has an FT Raman spectrum with a peak at about 233 cm -1 、334cm -1 、415cm -1 、490cm -1 、540cm -1 、575cm -1 、596cm -1 、625cm -1 、642cm -1 、680cm -1 、699cm -1 、719cm -1 、757cm -1 、791cm -1 、810cm -1 、838cm -1 、879cm -1 、899cm -1 、1010cm -1 、1060cm -1 、1080cm -1 、1134cm -1 、1204cm -1 、1234cm -1 、1288cm -1 、1345cm -1 、1359cm -1 、1374cm -1 、1437cm -1 、1556cm -1 、1576cm -1 、1608cm -1 、2867cm -1 、2928cm -1 、3062cm -1 and 3114cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (c) has an ATR-FTIR spectrum with a peak at about 676 cm -1 、716cm -1 、746cm -1 、774cm -1 、784cm -1 、838cm -1 、868cm -1 、904cm -1 、933cm -1 、1009cm -1 、1043cm -1 、1077cm -1 、1125cm -1 、1175cm -1 、1216cm -1 、1249cm -1 、1286cm -1 、1301cm -1 、1370cm -1 、1457cm -1 、1470cm -1 、1533cm -1 、1587cm -1 、1651cm -1 、2863cm -1 、2927cm -1 、3041cm -1 、3223cm -1 and 3437cm -1 ±2cm -1 The wavenumbers include absorption bands.
23. The crystalline form according to claim 22, That: (a) having an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 11; and / or (b) having a FT Raman spectrum substantially the same as that shown in FIG. 12 ; and / or (c) has substantially the same ATR-FTIR spectrum as that shown in FIG. 13 .
24. 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid according to claim 2, which is amorphous.
25. The amorphous compound according to claim 24, That: (a) has an FT Raman spectrum with a peak at about 1296 cm -1 、1608cm -1 、2928cm -1 and 3060cm -1 ±2cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (b) has an ATR-FTIR spectrum with a peak at about 742 cm -1 、778cm -1 、1379cm -1 and 1536cm -1 ±2cm -1 The absorption band is included at the wave number of .
26. The amorphous compound according to claim 25, (a) has an FT Raman spectrum with a peak at about 335 cm -1 、415cm -1 、544cm -1 、641cm -1 、684cm -1 、759cm -1 、801cm -1 、845cm -1 、879cm -1 、910cm -1 、1011cm -1 、1061cm -1 、1077cm -1 、1137cm -1 、1203cm -1 、1296cm -1 、1359cm -1 、1386cm -1 、1438cm -1 、1556cm -1 、1579cm -1 、1608cm -1 、2862cm -1 、2927cm -1 and 3060cm -1 ±2cm -1 includes absorption bands at wave numbers of; and / or (b) has an ATR-FTIR spectrum with a peak at about 679 cm -1 、716cm -1 、742cm -1 、778cm -1 、842cm -1 、869cm -1 、928cm -1 、1010cm -1 、1043cm -1 、1078cm -1 、1127cm -1 、1182cm -1 、1224cm -1 、1285cm -1 、1379cm -1 、1455cm -1 、1537cm -1 、1589cm -1 、1632cm -1 、2863cm -1 、2926cm -1 、3047cm -1 and 3255cm -1 ±2cm -1 The wavenumbers include absorption bands.
27. The amorphous compound according to claim 26, That: (a) having substantially the same FT Raman spectrum as that shown in FIG. 9 ; and / or (b) has substantially the same ATR-FTIR spectrum as shown in FIG. 17 .
28. The crystalline form of claim 3 having wavelengths at 6.93, 7.28, 12.11, 14.52, 15.04, 15.73, 19.44 and 22.00 [° 2θ ± 0.2° 2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
29. The crystalline form of claim 28 having a relative humidity of 6.93, 7.28, 8.07, 10.08, 12.11, 13.53, 13.92, 14.52, 15.04, 15.73, 16.21, 16.96, 17.57, 18.13, 18.46, 19.31, 19.44, 19.87, 20.25, 20. .51, 20.97, 22.00, 22.29, 22.49, 22.93, 23.12, 23.33, 23.60, 24.03, 24.40, 24.92, 25.04, 25.26, 25.62, 25.86, 26.15, 26.52, 27.26, 28.66, and 30.58 [°2θ ± 0.2°2θ, Cu Kα radiation ] includes an X-ray powder diffraction (XRPD) pattern of peaks at ].
30. The crystalline form of claim 28, having an X-ray powder diffraction (XRPD) pattern substantially the same as that shown in Figure 18.
31. A pharmaceutical composition comprising a compound according to any one of claims 1 to 30 or a mixture thereof, and at least one additional component selected from pharmaceutically acceptable carriers, diluents and excipients.
32. The pharmaceutical composition of claim 31, wherein the pharmaceutical composition is in a form suitable for intravenous administration to a mammal.
33. A solution for intravenous administration to a mammal, the solution comprising: (i) a compound according to any one of claims 1 to 30; (ii) water for injection; and (iii) Sodium chloride.
34. The solution for intravenous administration according to claim 33, wherein the concentration of the compound according to any one of claims 1 to 30 is 50 mg / mL.
35. A compound according to any one of claims 1 to 30 for use as a medicament.
36. A compound according to any one of claims 1 to 30 for use in the treatment of bacterial infections and diseases caused thereby in mammals.
37. A method for treating bacterial infection and diseases caused thereby in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a compound according to any one of claims 1 to 30.
38. Use of a compound according to any one of claims 1 to 30 in a method according to claim 37.
39. Use of a compound according to any one of claims 1 to 30 in the manufacture of a medicament for treating bacterial infections and diseases caused thereby in mammals.
40. The invention as herein before described.
